2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Lymphoid
1
Conditions
Primary Myelofibrosis
41
Myeloproliferative Disorders
30
Polycythemia Vera
28
Leukemia, Myeloid, Acute
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia
17
Myelodysplastic Syndromes
15
Thrombocythemia, Essential
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Neoplasms
9
Multiple Myeloma
9
Graft vs Host Disease
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Leukemia, Myelomonocytic, Chronic
8
Recurrence
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Non-Hodgkin
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
6
Prostatic Neoplasms
5
Lymphoma, T-Cell
5
Lymphoma
5
Leukemia, Myeloid, Chronic-Phase
5
Hodgkin Disease
5
Hematologic Diseases
5
Colorectal Neoplasms
5
Thrombocytosis
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Carcinoma, Non-Small-Cell Lung
4
Interventions
Etoposide
7
pegaspargase
5
Methylprednisolone
4
Dexamethasone
4
Cyclophosphamide
3
Alemtuzumab
3
Gemcitabine
2
Flow Cytometry
2
Emapalumab
2
Doxorubicin
2
zanubrutinib
1
tocilizumab
1
sintilimab
1
ruxolitinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Vincristine
1
Thiotepa
1
Th1-Th2 Balance
1
Tacrolimus
1
Rituximab
1
Prednisone
1
Polymerase Chain Reaction
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Methylprednisolone Hemisuccinate
1
Methotrexate
1
Melphalan
1
In Situ Hybridization
1
Immunohistochemistry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphohistiocytosis, Hemophagocytic
×
ruxolitinib
×
Clear all
NCT04999878
2021-08-11
RUE-DDGP
Zhengzhou University
Phase 4
Unknown
30 enrolled